Evidence map›Paper›PMID 41588134›Full record

ReviewEuropean journal of pediatrics2026

Follow-up of neonates who received ECMO: how are they doing?

Elena Rodríguez Corrales, Sara Vigil Vázquez, Ana Belén Bernardo Atienza, Manuel Sánchez Luna

Abstract readReview
PubMed Publisher
In one paragraph

Review in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Elena Rodríguez CorralesDepartment of Neonatology, Gregorio Marañon University Hospital, Madrid, Spain. elenarodriguezcorrales@gmail.com.ORCID http://orcid.org/0000-0003-2855-5000
Sara Vigil VázquezDepartment of Neonatology, Gregorio Marañon University Hospital, Madrid, Spain.ORCID http://orcid.org/0000-0002-5220-8087
Ana Belén Bernardo AtienzaDepartment of Neonatology, Gregorio Marañon University Hospital, Madrid, Spain.ORCID http://orcid.org/0000-0003-1684-9060
Manuel Sánchez LunaDepartment of Neonatology, Gregorio Marañon University Hospital, Madrid, Spain.ORCID http://orcid.org/0000-0001-9543-7392

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extracorporeal membrane oxygenation (ECMO) has been used since 1975 to provide temporary cardiorespiratory support in neonates, children, and adults with severe cardiopulmonary conditions unresponsive to conventional therapy. Initially focused on neonatal respiratory failure, ECMO indications have expanded to include older children with cardiac failure or post-cardiopulmonary arrest. Epidemiological data indicate a decline in neonatal respiratory ECMO cases over the recent decades, largely due to advances in conventional therapies. Conversely, neonatal cardiac ECMO has shown a more variable trend, often used perioperatively in congenital heart disease or for myocarditis, cardiomyopathy, and refractory arrhythmias. Survival rates remain relatively stable, although outcomes vary with underlying pathology and disease severity. Long-term follow-up of survivors reveals persistent respiratory, neurodevelopmental, and motor sequelae, particularly in patients with complex or chronic conditions such as congenital diaphragmatic hernia or hypoxic-ischemic encephalopathy. Pulmonary function deficits, cognitive impairments, hearing loss, and motor delays are frequently reported, with earlier rehabilitation and structured follow-up programs shown to improve functional recovery. Multicenter registries highlight the need for standardized assessment protocols to track long-term outcomes and guide interventions.

conclusionWhile neonatal ECMO has become a life-saving intervention for increasingly complex cases, ongoing efforts to refine patient selection, improve management strategies, and implement structured long-term follow-up are essential to minimize morbidity and maximize functional recovery in this vulnerable population. WHAT IS KNOWN: • Neonatal ECMO provides life-saving support for infants with severe cardiopulmonary failure when conventional therapies fail. • Survival rates vary depending on the underlying diagnosis, with respiratory ECMO generally showing higher survival than cardiac or extracorporeal cardiopulmonary resuscitation cases. WHAT IS NEW: • The neonatal ECMO population has become more complex, with higher-risk patients and more prolonged support requirements. • Long-term follow-up reveals that many ECMO survivors continue to face respiratory, neurological, or developmental sequelae.

Indexed as

Extracorporeal Membrane OxygenationRespiratory InsufficiencyFollow-Up StudiesHumansInfant, Newborn

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.